Evaluation of Sarcopenia Using Biomarkers of the Neuromuscular Junction in Parkinson’s Disease

• Published in: Journal of molecular neuroscience Vol. 72; no. 4; pp. 820 - 829
• Main Authors: Karim, Asima, Iqbal, M. Shahid, Muhammad, Tahir, Qaisar, Rizwan
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-04-2022; Springer Nature B.V
• Subjects: Age; Agrin; Biomarkers; Biomedical and Life Sciences; Biomedicine; Brain-Derived Neurotrophic Factor; Cell Biology; Diagnosis; Evaluation; Glial Cell Line-Derived Neurotrophic Factor; Glial cells; Hand Strength - physiology; Humans; Male; Movement disorders; Muscles; Neurochemistry; Neurodegenerative diseases; Neurology; Neuromuscular Junction; Neuromuscular junctions; Neuronal-glial interactions; Neurosciences; Parkinson Disease - diagnosis; Parkinson's disease; Proteomics; Rehabilitation; Sarcopenia; Sarcopenia - diagnosis; Stability analysis; Sarcopenia; GDNF; BDNF; CAF22; Parkinson’s disease
• ISSN: 0895-8696; 1559-1166
• DOI: 10.1007/s12031-022-01970-7

Patients with Parkinson’s disease (PD) present with an advanced form of age-related muscle loss or sarcopenia. However, the search for a biomarker to accurately predict muscle loss in PD remains elusive. We evaluated the biomarkers of neuromuscular junction (NMJ) stability, including c-terminal agrin fragment-22 (CAF22), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) as predictors of muscle wasting and physical capacity in PD. Male, 63—78 years patients of PD, were investigated for physical capacity, handgrip strength (HGS), and circulating biomarkers at the diagnosis and follow-up during rehabilitation 6 months apart. Patients with PD presented with elevated CAF22 and reduced BDNF and GDNF levels, which were partially restored to normal levels with rehabilitation. All three biomarkers showed significant dynamic associations with HGS and indexes of sarcopenia. Logistic regression revealed that the combination of biomarkers levels into a cumulative risk score enhanced the diagnostic accuracy of sarcopenia. In brief, measurements of plasma BDNF, GDNF, and CAF22 may be helpful in timely diagnosis and/or evaluation of sarcopenia.